Similarly, we treated patient-derived anthracycline-resistant AML cells with 0.3 μM chidamide and found that the expression levels of HDAC3, AKT, and CDK2 decreased while P21 expression increased, compared to control cells (Fig. 5b and c). The gene discussed is AKT1; the disease is acute myeloid leukemia.